Dr Burzynski
Stanislaw R. Burzynski, M.D., Ph.D., internationally recognized physician and biochemist-researcher who pioneered the development and use of biologically active peptides in diagnosing, preventing and treating cancer, since 1967.
Dr. Burzynski
In 1967, at the young age of 24, S.R. Burzynski graduated from the Medical Academy in Lublin, Poland, with a M.D. degree with distinction, finishing first in his class of 250. During the same year he identified naturally occurring peptides in the human body which he concluded control cancer growth. He found that there is a marked deficiency of these peptides in cancer patients.
The following year, 1968, he earned his Ph.D. in Biochemistry as one of the youngest candidates in Poland ever to hold both an M.D. and Ph.D.
From 1970 to 1977, while a researcher and Assistant Professor at Baylor College of Medicine in Houston, his research was sponsored and partially funded by the National Cancer Institute. At Baylor, he authored and co-authored 16 publications, including 5 concerning his research on peptides and their effect on human cancer. Four of these publications were also co-authored by other doctors associated with M.D. Anderson Hospital and Tumor Institute, and Baylor College of Medicine. It was at Baylor that Dr. Burzynski named these peptides “Antineoplastons” due to their activity in correcting and normalizing neoplastic, or cancerous, cells.
In May of 1977, Dr. Burzynski received a Certificate of Appreciation from Baylor College of Medicine, commending him for completing five years of dedicated service and acknowledging his contributions made to the “Advancement of Medical Education, Research, and Health Care.”
That same year, Dr. Burzynski founded his clinic in Houston where he’s since treated over 8,000 patients. He is also the president of the Burzynski Research Institute, where he continues to pursue scientific research on Antineoplastons.
Dr. Burzynski is a member in good standing of renowned medical associations, including the American and World Medical Associations, American Association for Cancer Research, Society for Neuroscience, Texas Medical Association, Royal Medical Association (U.K.), Academy of Medical Ethics, Society for Neuro-Oncology, and many others.
Dr. Burzynski is the author and co-author of over 300 scientific publications and presentations. In his career he has received numerous prestigious awards from various medical, educational and governmental institutions. Currently, he holds 242 patents registered in 35 countries, related to 17 proprietary scientific inventions (as of January 2011).
Other groups of scientists have expanded Dr. Burzynski’s work, including researchers at the National Cancer Institute, the Medical College of Georgia, the Imperial College of Science and Technology of London, the University of Kurume Medical School in Japan, the University of Turin Medical School in Italy, and many others. There are several hundred publications on Antineoplastons and their active ingredients written by scientists working independently of the Burzynski Research Institute.
Chemically, the Antineoplastons include peptides, amino acid derivatives and organic acids. They occur naturally in blood and urine and they are reproduced synthetically for medicinal use. The name of Antineoplastons comes from their functions in controlling neoplastic, or cancerous, cells (anti-neoplastic cells agents).
How do Antineoplastons work?Antineoplastons act as molecular switches, which turn off life processes in abnormal cells and force them to die through apoptosis (programmed death of a cell). While they trigger the death of cancer cells, they do not inhibit normal cell growth. They specifically target cancer cells without harming healthy cells.
It is generally known that the cancerous process results from increased activity of oncogenes and decreased expression of tumor suppressor genes. Antineoplastons “turn on” tumor suppressor genes and “turn off” oncogenes restoring the proper balance in gene expression.
Download full Curriculum Vitae of Dr. Burzynski
PRESS RELEASES
- Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility – September 28, 2009 (PDF)
- Burzynski Research Institute Announces Presents Positive Results from Phase II Trials of ANP for Inoperable Brainstem Glioma at the Congress – May 11, 2009 (PDF)
- Burzynski Research Institute Announces Positive Results of Phase II ANP Clinical Trial – May 6, 2009 (PDF)
- Physicians from the Burzynski Clinic Present Initial Results of Combination Gene-Targeting Therapies on Advanced Pancreatic and Liver Cancers – February 5, 2009 (PDF)
- Burzynski Research Institute Partners with Premier Research to Manage Phase III Clinical Study of Children with Newly-Diagnosed Diffuse Intrinsic Brainstem Glioma -January 26, 2009 (PDF)
- Burzynski Research Institute Gets SPA Clearance from the FDA to Initiate Pivotal Phase III Trial of Combination Antineoplaston Therapy and Radiation Therapy -January 13, 2009 (PDF)
- U.S. FDA Grants Orphan Drug Designation for Burzynski Research Institutes Antineoplaston Treatment for Gliomas – December 2, 2008 (PDF)
- Burzynski Research Institute, Inc. Presents Promising Phase II Data on Malignant Glioma -November 21, 2008 (PDF)
- Thought Leaders from Burzynski Research Institute Inc Present Encouraging Data on Antineoplastons for Treatment of Malignant Gliomas – November 20, 2008 (PDFA)
Additional reading:
